company logo

Medical Director/Senior Medical Director Rare Genetic Diseases (RGD) in Cambridge, MA

Agios Pharmaceuticals

Cambridge, MA 02138
6w ago


Medicine, Healthcare Management


Less than 5 years

Job Description

Agios is a biopharmaceutical company committed to applying our scientific leadership in cellular metabolism to transform the lives of patients with cancer and rare genetic diseases. We are growing rapidly with an active research and discovery pipeline across both therapeutic areas. Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.

We are currently seeking an innovative Clinical Development leader to help drive our rare disease development program. Reporting into our Vice President for Rare Genetic Diseases (RGD), this person will advance Agios' research activities and pipeline targeting Inborn Errors of Metabolism (IEMs).

The Medical Director/Senior Medical Director will be responsible for the development and execution of clinical research and development programs for Agios Pharmaceuticals including the leadership of the pivotal trials, NDA and filing activities.

See More

Valid through: 2020-3-5

About Agios Pharmaceuticals

Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.:Table 1 In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios. In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.
Total Jobs:
Average Pay:
Total value of jobs:
% Masters:
* Ladders Estimates